Lifeline Scientific, Inc Strategic Review (5926Z)
2015年9月21日 - 3:00PM
ＲＮＳを含む英国規制内ニュース （英語）
TIDMLSIC
RNS Number : 5926Z
Lifeline Scientific, Inc
21 September 2015
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Strategic review
Lifeline set to explore strategic and financial alternatives
aimed to increase shareholder value
Lifeline Scientific (AIM: LSIC), the transplantation technology
company, announces that its Board of Directors has determined to
explore a full range of strategic and financial alternatives to
enhance shareholder value, and the Company has retained Piper
Jaffray to assist in the process.
The Board believes that the Company is at an inflection point in
its growth, and that opportunities represented by its existing
business combined with China's Food and Drug Administration (CFDA)
approvals of LifePort Kidney Transporter and related single-use
consumables and solutions, recent progress in Brazil and the
prospects of LifePort Liver Transporter, are not reflected in the
Company's current market value. Consequently the Board plans to
explore a range of options, which could include (though will not be
limited to), a strategic merger, strategic acquisitions, a
potential sale of the Company, and a potential listing of the
Company's shares on the NASDAQ market.
Commenting David Kravitz, CEO of Lifeline Scientific, said:
"Our board is focused on maximising shareholder value in this
time of significant opportunity within the global transplant
market. Accordingly, we will thoroughly explore the full range of
strategic and financial alternatives available to capitalise on our
market-leading platform of LifePort based organ recovery and
preservation products, and our premium global brand. All options
will be thoroughly reviewed and we will take the time we require to
evaluate our opportunities, and achieve the best results for our
shareholders, business partners and associates."
The Board is at the beginning stage of its strategic and
financial review, and no assurance can be given as to its outcome
or timing. The Company does not presently intend to make any
further public comment regarding the review unless and until the
board approves the outcome of the review.
For further information:
Lifeline Scientific, Inc www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Panmure Gordon (UK) Ltd Tel: +44 (0)20 7886 2500
Freddy Crossley (Corporate
Finance)
Maisie Atkinson (Corporate
Broking)
Piper Jaffray Ltd Tel: +44(0) 20 7796 8400
Neil Mackison
Graeme Smethurst
Walbrook PR Ltd Tel: +44 (0) 20 7933 8780 or lifeline@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Mike Wort Mob: +44 (0)7900 608 002
About Lifeline Scientific, Inc
Lifeline Scientific, is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to help improve kidney preservation, evaluation and
transport prior to transplantation. It has been widely studied in
clinical trials throughout the world and is the standard of care
for machine preservation of kidneys. Employed by surgeons in over
200 leading transplant programmes in 29 countries, LifePorts have
preserved more than 70,000 kidneys indicated for clinical
transplant. For more information please visit
www.organ-recovery.com
About LifePort Liver Transporter
LifePort Liver Transporter is modelled upon the clinically
proven technology platform of LifePort Kidney Transporter and the
Company's early HMP prototype successfully used in clinical
transplant studies by surgeons at New York-Presbyterian
Hospital/Columbia University Medical Center. LifePort Liver
Transporter and the Company's proprietary machine preservation
solution, Vasosol(R), are in the process of US and European
regulatory registrations. The system is designed to help improve
outcomes in liver transplantation by enabling the clinical use of
hypothermic machine preservation, and has been developed in
consultation with clinical and research teams specializing in liver
transplantation at Columbia University Medical Center and the
University of Chicago. The system employs a rugged, streamlined
ergonomic design for ease of use and transportability from donor
bedside to recipient operating room. For more information please
visit: http://www.organ-recovery.com/pipeline.php
This announcement is for information purposes only and is not
intended to, and does not, constitute or form part of any offer,
invitation or the solicitation of an offer to purchase, otherwise
acquire, subscribe for, sell or otherwise dispose of, any
securities, whether pursuant to this announcement or otherwise. The
distribution of this announcement in jurisdictions outside the
United Kingdom may be restricted by law and therefore persons into
whose possession this announcement comes should inform themselves
about, and observe, such restrictions. Any failure to comply with
the restrictions may constitute a violation of the securities laws
of any such jurisdiction
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCVBLFLEKFEBBZ
(END) Dow Jones Newswires
September 21, 2015 02:00 ET (06:00 GMT)
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 6 2024 まで 7 2024
Lifeline Sci (LSE:LSIC)
過去 株価チャート
から 7 2023 まで 7 2024
